Q1 EPS Estimate for Vertex Pharmaceuticals Raised by Analyst

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Investment analysts at Zacks Research boosted their Q1 2025 earnings per share (EPS) estimates for Vertex Pharmaceuticals in a research report issued to clients and investors on Monday, March 3rd. Zacks Research analyst R. Department now anticipates that the pharmaceutical company will post earnings per share of $3.61 for the quarter, up from their prior estimate of $3.51. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q2 2025 earnings at $3.70 EPS, Q3 2025 earnings at $3.90 EPS, Q4 2025 earnings at $4.01 EPS, FY2025 earnings at $15.22 EPS, Q1 2026 earnings at $3.82 EPS, Q2 2026 earnings at $3.95 EPS, Q4 2026 earnings at $4.29 EPS and FY2026 earnings at $16.18 EPS.

VRTX has been the subject of a number of other reports. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Piper Sandler lowered their target price on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Scotiabank raised their target price on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the company a “sector perform” rating in a report on Tuesday, February 11th. Royal Bank of Canada increased their price objective on shares of Vertex Pharmaceuticals from $407.00 to $408.00 and gave the company a “sector perform” rating in a research report on Thursday, February 20th. Finally, Jefferies Financial Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $500.00 to $550.00 in a research report on Monday, December 9th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $506.70.

Vertex Pharmaceuticals Price Performance

VRTX opened at $491.64 on Thursday. Vertex Pharmaceuticals has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a 50 day moving average of $445.18 and a two-hundred day moving average of $461.33. The company has a market cap of $126.25 billion, a P/E ratio of -223.47, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several institutional investors have recently made changes to their positions in VRTX. Dunhill Financial LLC increased its position in Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the period. Legacy Investment Solutions LLC bought a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at about $33,000. Brown Lisle Cummings Inc. acquired a new position in Vertex Pharmaceuticals during the 4th quarter valued at about $30,000. Truvestments Capital LLC acquired a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $35,000. Finally, Capital Performance Advisors LLP acquired a new position in shares of Vertex Pharmaceuticals during the third quarter worth approximately $39,000. 90.96% of the stock is owned by institutional investors.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 530 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $475.34, for a total transaction of $251,930.20. Following the sale, the executive vice president now owns 58,539 shares in the company, valued at $27,825,928.26. This represents a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders have sold 1,084 shares of company stock worth $505,512. 0.20% of the stock is currently owned by insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.